Zacks Research Analysts Lower Earnings Estimates for CORT

Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Investment analysts at Zacks Research decreased their Q1 2026 earnings estimates for Corcept Therapeutics in a research note issued to investors on Thursday, May 29th. Zacks Research analyst K. Das now forecasts that the biotechnology company will earn $0.23 per share for the quarter, down from their previous forecast of $0.27. The consensus estimate for Corcept Therapeutics' current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics' Q1 2027 earnings at $0.67 EPS and FY2027 earnings at $3.97 EPS.

CORT has been the subject of a number of other research reports. Canaccord Genuity Group raised their price objective on Corcept Therapeutics from $130.00 to $142.00 and gave the company a "buy" rating in a research note on Tuesday, April 1st. Piper Sandler boosted their price target on shares of Corcept Therapeutics from $128.00 to $131.00 and gave the stock an "overweight" rating in a research report on Thursday, April 3rd. Truist Financial set a $135.00 target price on Corcept Therapeutics in a report on Tuesday, May 6th. HC Wainwright decreased their target price on Corcept Therapeutics from $150.00 to $145.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Finally, Wall Street Zen cut shares of Corcept Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, May 14th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $138.25.

Corcept Therapeutics Trading Down 3.0%

CORT stock traded down $2.17 during midday trading on Monday, reaching $69.51. 2,476,615 shares of the company's stock traded hands, compared to its average volume of 1,147,408. The business has a 50-day moving average price of $72.82 and a two-hundred day moving average price of $63.53. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. Corcept Therapeutics has a fifty-two week low of $28.04 and a fifty-two week high of $117.33. The company has a market capitalization of $7.37 billion, a P/E ratio of 55.17 and a beta of 0.22.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The biotechnology company reported $0.17 earnings per share for the quarter, hitting analysts' consensus estimates of $0.17. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The business had revenue of $157.21 million during the quarter, compared to analysts' expectations of $177.93 million. During the same period last year, the company posted $0.25 EPS. The company's revenue was up 7.1% on a year-over-year basis.

Insider Activity

In other Corcept Therapeutics news, insider Joseph Douglas Lyon sold 421 shares of Corcept Therapeutics stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $60.58, for a total transaction of $25,504.18. Following the transaction, the insider now directly owns 9,009 shares in the company, valued at approximately $545,765.22. The trade was a 4.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David L. Mahoney sold 27,352 shares of the stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $74.23, for a total value of $2,030,338.96. The disclosure for this sale can be found here. In the last ninety days, insiders sold 275,125 shares of company stock valued at $23,619,296. Company insiders own 20.80% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Focus Partners Wealth increased its position in shares of Corcept Therapeutics by 0.5% during the 1st quarter. Focus Partners Wealth now owns 33,243 shares of the biotechnology company's stock worth $3,797,000 after purchasing an additional 170 shares during the last quarter. Brooklyn Investment Group boosted its holdings in shares of Corcept Therapeutics by 99.5% in the 1st quarter. Brooklyn Investment Group now owns 373 shares of the biotechnology company's stock valued at $43,000 after buying an additional 186 shares during the last quarter. Black Diamond Financial LLC grew its stake in shares of Corcept Therapeutics by 4.0% in the fourth quarter. Black Diamond Financial LLC now owns 5,200 shares of the biotechnology company's stock valued at $262,000 after buying an additional 200 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in Corcept Therapeutics by 3.0% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 7,954 shares of the biotechnology company's stock worth $909,000 after buying an additional 230 shares during the last quarter. Finally, Quadrant Capital Group LLC raised its position in Corcept Therapeutics by 9.5% during the fourth quarter. Quadrant Capital Group LLC now owns 2,969 shares of the biotechnology company's stock worth $150,000 after acquiring an additional 257 shares in the last quarter. Institutional investors and hedge funds own 93.61% of the company's stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.